GLP-1 Medications: Who Responds Best?

Key Takeaways

• Genetic differences in GLP-1 and GIP receptors may help explain why some people respond better to certain incretin therapies than others, pointing toward a future of more personalized prescribing.
• People taking GLP-1 receptor agonists report meaningful reductions in food cravings and improvements in dietary quality, though changes in lean muscle mass also warrant attention.
• A large cohort study found tirzepatide was associated with a reduced risk of pulmonary embolism and deep vein thrombosis compared with other treatments, though more research is needed.
• Compounded GLP-1 products flooded the market during drug shortages, and their quality, dosing accuracy, and safety are not regulated the same way as FDA-approved medications.
• Older adults face unique considerations — including muscle loss, fall risk, and kidney function — that make close medical supervision especially important when using GLP-1 medications.

What Are GLP-1 Medications and How Do They Compare to Other Weight-Loss Options?

GLP-1 medications are a class of prescription drugs that mimic a natural gut hormone to reduce appetite and slow digestion. Head-to-head research shows they produce significantly greater weight loss than older prescription options. Here's what that means in practice — and how these medications fit into the broader landscape of weight-loss tools.

---

What "GLP-1" actually means

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut releases after you eat. It signals your brain that you're full, slows the rate at which food leaves your stomach, and helps regulate blood sugar. GLP-1 receptor agonists (the full name for this drug class) are medications that activate the same "full" signal, but more consistently and for longer than the natural hormone does.

---

How GLP-1 medications compare to other options

A 2025 systematic review and network meta-analysis — a study design that pools and ranks evidence from many trials — found that GLP-1 and dual-action GLP-1/GIP medications (like tirzepatide, which targets two hormones at once) produced meaningfully greater weight loss compared with older prescription weight-loss drugs such as orlistat or phentermine-topiramate.

Key distinctions:

• Older prescription medications generally work through different mechanisms — blocking fat absorption or suppressing appetite via the nervous system — and tend to produce more modest results than current GLP-1 options, according to the same meta-analysis.
• Bariatric surgery remains one of the most effective long-term interventions for severe obesity. A large cancer-risk comparison study noted that GLP-1 medications are increasingly being studied alongside bariatric surgery as a reference point — a sign of how seriously researchers now take their impact.
• Lifestyle change alone (diet, exercise, fasting) produces real benefits but typically less total weight loss than when combined with medication, which is why many people use both together.

---

Beyond the scale

GLP-1 medications appear to affect more than body weight. Research published in The CRAVE Study found that people on GLP-1 therapy reported meaningful reductions in food cravings and improvements in dietary quality — not just eating less, but wanting different foods. A multicenter U.S. cohort study found tirzepatide was associated with reduced risk of serious blood clots, suggesting potential benefits that extend beyond weight loss alone.

---

⚠️ This content is for general informational purposes only and is not medical advice. It does not replace a conversation with your doctor, pharmacist, or a qualified healthcare provider who knows your full health history.

Why Do Some People Respond Better to GLP-1 Medications Than Others?

Not medical advice: This content is for general informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making changes to your medication, diet, or health routine.

---

People respond differently to GLP-1 medications because of genetic differences, age, starting health status, lifestyle habits, and medication consistency — and no single factor fully predicts who will see the best results. Understanding these variables can help you set realistic expectations and work more effectively with your care team.

Genetics may play a role — but it's not destiny

Your DNA can influence how well GLP-1 drugs work for you. Variations in genes that code for GLP-1 and GIP receptors (the docking sites these medications attach to in your body) may affect how strongly your body responds to the drug's appetite- and blood-sugar-regulating signals. According to research on incretin therapy personalization, specific receptor gene variants have been studied as potential predictors of treatment response — though this science is still developing and genetic testing is not yet standard clinical practice.

What else shapes your response

Several well-documented factors influence outcomes:

• Starting diet quality and cravings: People who experience strong reductions in food cravings tend to eat fewer calories and improve diet quality more dramatically. The CRAVE study found meaningful changes in food cravings, dietary intake, and body composition during GLP-1 therapy — suggesting that how much the medication suppresses your appetite drive is itself a key variable.

• Age: Older adults may face a different response profile. A review focused on older adults notes that slower metabolism, muscle loss risk, and concurrent medications can all affect how GLP-1 drugs perform and their safety in this population.

• Which medication and dose: Not all GLP-1 drugs are identical. A large systematic review and network meta-analysis comparing weight-loss drugs found meaningful differences in average weight loss across agents — meaning the specific drug prescribed matters.

• Consistency of use: Stopping and restarting, or using compounded (non-brand-name) versions of uncertain potency, can affect results. Research tracking GLP-1 prescribing patterns highlights that persistence — staying on the medication consistently — is a key factor in real-world outcomes.

The practical takeaway

If your results feel slower than expected, discuss this with your provider rather than discontinuing treatment. Response is shaped by biology and behavior, which means the lifestyle work you're doing alongside the medication — including fasting and food quality — genuinely matters and can help close the gap.

What Changes Can You Expect in Cravings, Diet, and Body Composition?

Most people on GLP-1 medications notice meaningful shifts in appetite, food preferences, and body composition — often within the first few weeks. Research confirms these changes are real and measurable, not simply a matter of willpower.

How Your Cravings Are Likely to Shift

GLP-1 medications work partly by acting on appetite-regulating signals in the brain, which can change what foods appeal to you. According to the CRAVE study, people on GLP-1 receptor agonists reported significant reductions in cravings — particularly for high-fat and sweet foods — alongside improvements in overall diet quality. Many people find that the pull toward ultra-processed or calorie-dense foods feels weaker.

• Sweet cravings tend to decrease noticeably, with many people reporting less interest in desserts, sugary drinks, and snacks — a finding documented in the CRAVE study.
• High-fat food cravings also drop, which can make it easier to choose whole foods without feeling deprived.
• Alcohol cravings may lessen for some people, though individual responses vary.

What Happens to Your Diet Overall

The CRAVE study found that people on GLP-1 therapy improved their dietary quality over time — eating more nutrient-dense foods and fewer empty calories. Portion sizes naturally shrink because the medication slows gastric emptying, which means you feel full sooner and stay full longer.

When combining this with a fasting approach, make every eating window count nutritionally, since your total food intake will likely be lower than before.

Body Composition Changes to Expect

Body composition refers to the ratio of fat to muscle in your body — not just the number on the scale.

• The CRAVE study documented reductions in body fat alongside overall weight loss in people using GLP-1 medications.
• Preserving muscle during weight loss requires deliberate effort — adequate protein intake and resistance exercise become especially important when appetite is suppressed and calorie intake drops.
• Weight loss with GLP-1 medications is generally gradual and sustained rather than rapid, which supports healthier body composition outcomes compared to crash dieting.

Individual Variation Matters

Not everyone responds the same way. Genetic differences in how your body processes these medications can influence your results, as noted in research on incretin therapy personalization. If your cravings or weight loss don't shift as expected, discuss this with your healthcare provider.

---

This content is for general informational purposes only and is not a substitute for personalized medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making changes to your medication, diet, or fasting routine.

Are There Emerging Safety Benefits — and Risks — Worth Knowing About?

Research is turning up genuinely exciting potential benefits from GLP-1 medications — but also emerging risks that deserve honest attention, especially when combined with fasting. Here's what the current evidence suggests.

---

Promising benefits researchers are watching closely

• Blood clot protection. A large U.S. study found that tirzepatide (a dual GIP/GLP-1 medication) was linked to meaningfully lower risk of pulmonary embolism and deep vein thrombosis compared to people not taking it. This finding could matter for anyone whose weight has raised their clot risk, per this multicenter cohort study.

• Reduced cancer risk signal. A comparison study found that GLP-1 receptor agonists were associated with lower rates of certain obesity-related cancers compared to other weight-loss approaches. However, researchers caution this area needs more study before drawing firm conclusions, per this cancer risk analysis.

• Improved food choices, not just less food. People on GLP-1 therapy in one study didn't just eat less — they also reported fewer cravings and shifted toward better-quality diets, suggesting the medication may support eating patterns that fasting protocols also encourage, per the CRAVE study.

• Response varies by genetics. Emerging research suggests that variations in GLP-1 and GIP receptor genes may influence how well a person responds to incretin-based therapy, meaning your results may differ from someone else's for biological reasons, per this pharmacogenomics review.

---

Risks that deserve equal attention

• Compounded medications carry real uncertainty. During and after drug shortages, a significant market for compounded (pharmacy-mixed) GLP-1 medications emerged. These products are not FDA-approved and may vary in dose, purity, and safety, per this compounded GLP-1 market study. If you're using a compounded version, discuss this with your prescriber.

• Older adults face specific added risks. For people over 65, GLP-1 medications combined with reduced calorie intake from fasting can accelerate muscle loss and increase fall risk — concerns that require tailored monitoring, per this older adult considerations review.

---

⚠️ Not medical advice. This section presents general health information for educational purposes only. It is not a substitute for personalized guidance from a licensed healthcare provider. Always consult your doctor or pharmacist before starting, stopping, or changing any medication or dietary practice.

What Should Older Adults and Special Populations Know Before Starting?

Older adults and people with certain health conditions need extra caution before combining GLP-1 medications with fasting, because both together can increase the risk of muscle loss, falls, nutrient gaps, and low blood sugar. Talk with your doctor or a registered dietitian before starting — this combination is not one-size-fits-all.

---

Why older adults face unique risks

GLP-1 medications significantly reduce appetite, which aids weight loss but can be problematic for older adults who may already eat too little. According to a clinical review on GLP-1 use in older adults (source), this population faces higher risk for:

• Sarcopenia (sar-koh-PEE-nee-ah) — age-related muscle loss. When calories drop sharply, the body breaks down muscle for energy, not just fat.
• Malnutrition — reduced food intake from GLP-1 medications may make it harder to meet daily needs for protein, calcium, vitamin D, and B vitamins.
• Falls and fractures — muscle weakness combined with dizziness (a possible side effect) increases fall risk, especially if fasting causes low blood pressure upon standing.
• Dehydration — older adults have a blunted thirst response, and fasting windows can worsen fluid loss.

The same review notes that weight loss in older adults requires careful attention to preserving lean muscle mass and bone density — goals that demand adequate protein and resistance exercise, not calorie reduction alone.

---

People with type 2 diabetes

If you take insulin or certain diabetes medications (sulfonylureas) alongside a GLP-1 medication, adding fasting can increase your risk of hypoglycemia — low blood sugar. Symptoms include shakiness, sweating, confusion, and fainting. Your medication doses may need adjustment before you begin fasting. Never change your diabetes medication without medical guidance.

---

Other groups who should seek individualized guidance first

• People with a history of eating disorders
• Those with kidney disease (fasting affects fluid and electrolyte balance)
• Anyone with a history of gallbladder problems (rapid weight loss can trigger gallstones)
• People on multiple medications, since GLP-1 drugs slow gastric emptying, which may alter how other medications are absorbed — a concern flagged in research on GLP-1 special considerations

---

⚠️ Not medical advice. This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual needs vary. Always consult a qualified healthcare professional before making changes to your medication, diet, or fasting routine.

What Are the Risks of Compounded GLP-1 Products?

Compounded GLP-1 products carry real safety risks that FDA-approved versions do not, primarily because they lack the same manufacturing oversight, purity testing, and dose verification. Understanding these risks can help you have a more informed conversation with your doctor.

What "compounded" means: A compounded medication is mixed by a pharmacy (or sometimes a manufacturer) outside the standard drug-approval process. It has not gone through the same clinical trials or quality checks as brand-name products like Ozempic or Zepbound.

---

Key risks to know:

• Uncertain purity and potency. Compounded versions may contain different salt forms of the active ingredient (for example, semaglutide acetate instead of semaglutide sodium), added ingredients not in the original formula, or inaccurate doses. Research tracking the post-shortage compounded GLP-1 market found a wide and largely unregulated variety of products available to consumers, raising concerns about consistency and safety — Postshortage Compounded GLP-1 Market.

-No guarantee the dose matches the label. Because compounding pharmacies are not held to the same manufacturing standards as pharmaceutical companies, the amount of active drug in each vial or pen may be higher or lower than stated. Too little means no benefit; too much raises the risk of serious side effects like severe nausea, vomiting, dehydration, or dangerously low blood sugar (hypoglycemia).

• Harder to track and monitor. Standard prescription records often miss compounded GLP-1 use entirely, making it difficult for your care team to monitor your full medication picture — AI curation of clinical notes. This gap matters especially if you are also fasting, since fasting already affects blood sugar and appetite in ways that interact with GLP-1 medications.

• No recourse if something goes wrong. FDA-approved drugs have established reporting systems and manufacturer accountability. Compounded products generally do not offer the same protections.

• Older adults face amplified risk. People over 65 are already at higher risk for dehydration, muscle loss, and falls while using GLP-1 medications — GLP-1 use in older adults. Unpredictable dosing from a compounded product adds another layer of concern for this group.

---

The bottom line: compounded GLP-1 products are not automatically unsafe, but the lack of standardized oversight means you are taking on unknowns that do not exist with approved medications. Always tell your healthcare provider exactly what you are taking — including the source — so they can help you weigh the risks against your specific situation.

---

This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

FAQ

How do GLP-1 medications compare to other weight-loss drugs?

A 2025 systematic review and network meta-analysis published in the BMJ found that GLP-1 receptor agonists and dual GLP-1/GIP agonists like tirzepatide ranked among the most effective options for weight loss in adults with overweight or obesity compared with other drug classes. However, individual results vary, and the best choice depends on your health history — something only your doctor can assess.

Can my genes affect how well a GLP-1 medication works for me?

Emerging research suggests yes. A 2025 review in the Journal of the Endocrine Society found that polymorphisms (natural variations) in GLP-1 and GIP receptor genes may influence how individuals respond to incretin-based therapies. This research is still evolving, but it points toward a future where genetic testing could help personalize medication choices.

Will GLP-1 medications change what I want to eat?

The CRAVE study, published in Obesity Pillars, found that people on GLP-1 receptor agonist therapy reported reductions in food cravings and improvements in overall dietary quality. However, the study also noted changes in body composition, including potential loss of lean mass, which is why nutrition and physical activity guidance from a healthcare professional is important alongside medication.

Is tirzepatide linked to any heart or blood clot benefits?

A 2025 multicenter U.S. cohort study published in Frontiers in Endocrinology found that tirzepatide was associated with a reduced risk of pulmonary embolism and deep vein thrombosis compared with certain other treatments. These are observational findings and do not prove cause and effect — discuss cardiovascular and clotting risk with your doctor.

Are compounded GLP-1 medications safe to use?

Compounded GLP-1 products expanded rapidly during drug shortages, but a 2025 JAMA Health Forum study found a significant compounded market persisting even after shortage designations ended. Unlike FDA-approved medications, compounded versions are not subject to the same manufacturing standards, potency verification, or safety review. Experts urge caution and consultation with a licensed healthcare provider before using any compounded product.

What special risks do older adults face with GLP-1 medications?

A 2025 review in Advances in Therapy highlighted that older adults using GLP-1 receptor agonists for obesity or type 2 diabetes face unique concerns, including accelerated muscle and bone loss, increased fall risk, changes in kidney function, and potential interactions with other medications. Older adults should work closely with their healthcare team to monitor these risks and adjust treatment plans as needed.

This article is for general information and is not medical advice. GLP-1 medications are prescription drugs, and fasting is not right for everyone — talk to a licensed healthcare provider before starting, stopping, or changing any treatment or eating pattern.